9.39
前日終値:
$9.15
開ける:
$9.06
24時間の取引高:
203.83K
Relative Volume:
0.14
時価総額:
$833.87M
収益:
$73.48M
当期純損益:
$-108.30M
株価収益率:
-4.1733
EPS:
-2.25
ネットキャッシュフロー:
$-67.17M
1週間 パフォーマンス:
+17.96%
1か月 パフォーマンス:
-1.78%
6か月 パフォーマンス:
+40.57%
1年 パフォーマンス:
+57.02%
Personalis Inc Stock (PSNL) Company Profile
PSNL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
PSNL
Personalis Inc
|
9.39 | 812.56M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
621.52 | 233.21B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.74 | 167.12B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.89 | 56.44B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.88 | 41.84B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
245.96 | 40.96B | 15.90B | 1.28B | 2.21B | 7.2842 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-02 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-05-15 | 開始されました | Guggenheim | Buy |
| 2025-03-17 | 開始されました | Craig Hallum | Buy |
| 2023-02-06 | アップグレード | Needham | Hold → Buy |
| 2022-01-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | ダウングレード | Needham | Buy → Hold |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-09-20 | 繰り返されました | Needham | Buy |
| 2021-05-06 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2021-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-12 | 繰り返されました | Needham | Buy |
| 2020-11-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-10-19 | 開始されました | Citigroup | Buy |
| 2020-10-08 | 開始されました | BTIG Research | Buy |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2019-09-26 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | 開始されました | BofA/Merrill | Neutral |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Morgan Stanley | Overweight |
| 2019-07-15 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Personalis Inc (PSNL) 最新ニュース
Personalis (NASDAQ:PSNL) delivers shareholders splendid 54% CAGR over 3 years, surging 15% in the last week alone - simplywall.st
Personalis (NASDAQ:PSNL) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Will Personalis Inc stock remain a Wall Street favoriteJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - moha.gov.vn
Quant Funds Rotate Into Pavna Industries Limited StockTechnical Analysis Insights & Stay Invested. Stay Smart. - earlytimes.in
Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) - Insider Monkey
Personalis Outpaces The Market With Cancer Test Breakthroughs - Finimize
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Will Personalis Inc. (04X) stock split increase liquidityRate Cut & Entry and Exit Point Strategies - Улправда
How Personalis Inc. stock reacts to bond yieldsWeekly Trading Summary & Safe Entry Point Alerts - ulpravda.ru
Is Personalis Inc. stock attractive for hedge funds2025 Bull vs Bear & Community Consensus Trade Signals - Улправда
Personalis (NASDAQ:PSNL) Sees Strong Trading VolumeHere's Why - MarketBeat
Will Personalis Inc. stock remain a Wall Street favoriteJuly 2025 Trends & Free High Return Stock Watch Alerts - Bölüm Sonu Canavarı
Nasdaq Moves: How Personalis Inc. stock reacts to bond yieldsWeekly Stock Recap & Reliable Price Action Trade Plans - ulpravda.ru
Aug Opening: How risky is Personalis Inc. stock nowTrade Exit Summary & Daily Price Action Insights - Улправда
Revenue Check: Will Personalis Inc. (04X) stock split increase liquidityJuly 2025 Price Swings & Daily Price Action Insights - Улправда
How risky is Personalis Inc. stock nowJuly 2025 Earnings & Safe Investment Capital Preservation Plans - Улправда
Personalis study shows cancer blood test predicts immunotherapy outcomes By Investing.com - Investing.com Nigeria
Personalis study shows cancer blood test predicts immunotherapy outcomes - Investing.com
Personalis announces new publication applying ultrasensitive ctDNA testing - marketscreener.com
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors - Business Wire
Personalis (NASDAQ:PSNL) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Personalis (NASDAQ:PSNL) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer - Business Wire
Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds - Yahoo Finance
Personalis, Inc. $PSNL Shares Purchased by Blue Water Life Science Advisors LP - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 38% But Its P/S Still Looks Reasonable - 富途牛牛
Personalis (NASDAQ:PSNL) Stock Price Down 4.8%What's Next? - MarketBeat
Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen - MarketBeat
Is Personalis Inc. (04X) stock undervalued by metricsEarnings Miss & Short-Term High Return Strategies - Newser
Geode Capital Management LLC Buys 851,422 Shares of Personalis, Inc. $PSNL - MarketBeat
Will Personalis Inc. (04X) stock maintain strong growthWeekly Volume Report & Growth Focused Investment Plans - Newser
Will Personalis Inc. (04X) stock beat Nasdaq index returns2025 Short Interest & Real-Time Volume Spike Alerts - Newser
Will Personalis Inc. (04X) stock outperform Dow JonesMarket Risk Summary & Fast Moving Market Watchlists - Newser
How Personalis Inc. stock performs during Fed tightening cycles2025 Growth vs Value & Weekly Chart Analysis and Trade Guides - Newser
Will Personalis Inc. stock reach Wall Street targetsInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Personalis (PSNL) Rating Maintained and Price Target Raised by M - GuruFocus
Personalis (NASDAQ:PSNL) Shares Gap Down After Insider Selling - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Q2 2025 Earnings Call Transcript - MSN
Morgan Stanley Raises Price Target on Personalis to $11 From $9, Keeps Equalweight Rating - marketscreener.com
Piper Sandler Healthcare Conference - MarketScreener
Personalis, Inc. (NASDAQ:PSNL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Personalis Inc (PSNL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):